logo-loader
viewANGLE PLC

ANGLE shares rise 11% after its tumour cell detection device is deployed in cancer advance

The Parsortix system was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer

1555570639_sareum-test-tubes.png
The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature

Shares in ANGLE PLC (LON:AGL) (OTCQX:ANPCY) rose 11% after it said its liquid biopsy system was used to assess the metastatic potential of breast cancer.

Metastasis is the process by which cancer spreads from its primary location.

READ: ANGLE ground-breaking liquid biopsy to be used in lung cancer study

Parsortix was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer. Researchers at the University of Texas MD Anderson Cancer Center then used a new technique called transmembrane receptor dynamics to distinguish between invasive cancer cells and less-invasive cells.

Being able to make such a distinction would allow doctors to offer more personalised treatments to patients.

The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature.

"This study is the 19th peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system,” said the company’ chief executive, Andrew Newland.

“We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities."

Broker finnCap said the peer-reviewed article provided “further independent endorsement of the utility of Parsortix”.

The shares were trading 7.5p higher at 76p.

---adds broker quote and share pric---

Quick facts: ANGLE PLC

Price: 79 GBX

AIM:AGL
Market: AIM
Market Cap: £136.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Zoetic reports 'significant' first half as CBD shift continues

Headlines from the Proactive UK newsroom. Zoetic International plc (LON:ZOE) reported higher revenues in its first half as the company continued its pivot towards the cannabidiol (CBD) markets. In a trading update the firm posted revenues of £1.15mln in the six months to the end of September,...

1 week, 5 days ago

2 min read